Structure Therapeutics disclosed mid‑stage results for its oral GLP‑1 candidate showing substantial placebo‑adjusted weight loss that rivals injectable competitors. In one trial, a 120‑mg dose produced ~12.1% weight loss at 36 weeks; higher titration to 240 mg yielded ~14.2% in the ongoing study. The data were tempered by high rates of gastrointestinal adverse events—nausea in about 65% and vomiting in 32% at some doses—prompting questions about tolerability and commercial differentiation versus peptide injectables. The market reacted briskly, with biotech equities linked to oral GLP‑1 programs moving sharply on the readouts.